Background It has been suggested that inhaled frusemide protects subjects with asthma against bronchoconstriction by enhancing the synthesis of prostaglandin E, (PGE,). To evaluate this hypothesis the effect of frusemide on PGE, production from nasal mucosa was studied. Methods Two main arachidonic acid metabolites produced by epithelial cells, PGE2 and 15-hydroxy 5,8,11,13-eicosatetraenoic acid (15-HETE), were measured by radioimmunoassay in nasal secretions obtained by nasal lavages with saline. Eleven healthy volunteers were randomly assigned to two study days, one week apart, in a double blind crossover study. Nasal instillation with three increasing doses of frusemide (5, 10, and 20 mg) proposed that frusemide might prevent bronchoconstriction by enhancing PGE2 synthesis.7 Furthermore, it is interesting to note that the protective effect of frusemide on bronchoconstriction is similar to the effect of disodium cromoglycate, a drug that also prevents asthma attacks induced by exposure to allergen, exercise, and distilled water.8 10 In a recent study, the authors reported that disodium cromoglycate effectively attenuates the release of 1 5-hydroxy,5,8, 11,1 3-eicosatetraenoic acid (1 5-HETE) after allergen provocation of the nasal mucosa." This study also reported a decrease in basal 15-HETE release from nasal mucosa by disodium cromoglycate in both rhinitic and healthy subjects." As comparable results for both frusemide and cromoglycate have been found, we considered that frusemide, like disodium cromoglycate, might protect against inflammatory reactions by inhibiting the release of 1 5-HETE.
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Frusemide increases diuresis in healthy subjects and it is therefore reasonable to speculate that it might also exert its effects on the release of arachidonic acid metabolites in the upper airway of healthy subjects. Because an accurate knowledge of the changes induced by frusemide in the production of chemical mediators in healthy subjects may help to better understand the mechanisms involved in its protective effect on bronchospastic reactions, we have carried out a study to evaluate the effects of frusemide on the release of the main eicosanoids (15-HETE and PGE2) produced by the respiratory epithelia.
Subjects and methods

POPULATION
Eleven healthy volunteers (eight men and three women) aged 35 (SD 5) years participated in the study. They were recruited from the staff of our institution. The criteria for inclusion were current good health and absence of any treatment at the time of the study. None of the volunteers had had a respiratory infection for at least three weeks and they did not take any anti-inflammatory medication during the week before the study. All subjects gave informed consent to participate in the study, which was approved by the research committee of our institution. Failure offruseniide to increase production ofprostaglandin E, in human nasal mucosa in vivo NASAL LAVAGE Nasal lavages were carried out according to the method described by Naclerio and coworkers.'2 Briefly, with the head tilted backward, 8 ml of normal saline (0-9% NaCl) was instilled into the nose (4 ml in each nasal cavity) while the subject refrained from breathing and swallowing. After about 10 seconds, the subjects expelled the mixture of saline and nasal secretions into polypropylene tubes, which were stored at -70°C until extraction. Nasal lavage recoveries in the present study were 5-5 (SD 0-1) ml (70 (SD 1)%).
RADIOIMMUNOASSAY OF ARACHIDONIC ACID METABOLITES
PGE2
Extraction of PGE, from nasal lavages was performed according to a method previously described.'3-6 Nasal lavages were centrifuged at 20 000 g at 4°C for 15 minutes. Aliquots of supernatant fluid (0-5 ml) were acidified at pH 3 and processed through C18 cartridge columns (Baker, Phillipsburgs, NJ, USA).
After washing with 10 ml acidified water and 20 ml petroleum ether, prostaglandins were eluted with 8 ml methyl formate, which was evaporated in a vacuum (Savant, Hicksville, NY, USA). Dried residues were redissolved in Tris buffer and PGE2 was determined by radioimmunoassay (RIA) as previously described with antiserum provided by the Institute Pasteur (Marnes la Coquette, France). Standard curves were generated from 1-9 to 500 pg/tube and samples were diluted 1:2-08. The recovery of radiolabelled 'H-PGE, used as an internal standard of the assay was 86-4%.
The precision of the RIA method has been defined by calculating the intra-assay coefficient of variation (CV) for 
15-HETE
The extraction of 1 5-HETE from nasal lavages was performed according to a method previously described. 14 1 ' Supernatant aliquots (2 ml) were processed without pH modification through C18 Baker cartridge columns. After a wash with 10 ml of water, 1 5-HETE was eluted with 5 ml methanol:water (9:1). Study design A double blind crossover study design was used. Subjects were randomly divided into two study days one week apart. After a basal nasal lavage (time 0), three increasing doses of frusemide (5, 10, and 20 mg) were nebulised into the right nasal cavity by a hand driven nebuliser at 0, 15, and 30 minutes. Nasal lavages were carried out 15 minutes after each dose of frusemide and 30 minutes after the last dose was administered (figs 1 and 2). Equal volumes of placebo solution (0-5, 1, and 2 ml of 0-9% NaCl) were instilled in the right nasal cavity in the same manner as frusemide. As the frusemide solution used in our study had a pH of 9, the placebo solution (initial pH 7-3) was adjusted to pH 9 by the addition of 0-1 M NaOH.
Analysis
Results are presented as mean (SE) values in pg/ml. The statistical evaluation was performed on a microcomputer (Macintosh II, Apple, Cupertino, CA, USA) with a statistical software package (Statview 512+, Brainpower Inc, Calabasas, CA, USA). Student's t test for paired sample analysis was used for statistical comparison between frusemide and placebo effects. Values <0-05 were considered statistically significant. 
Results
Basal 15-HETE production, 814 (270) pg/ml on the placebo day and 869 (354) pg/ml on the frusemide day (n=11) was at least six times higher than basal PGE2 production, 125 5 (21) pg/ml and 130 (17) pg/ml (n= l 1). Basal concentrations of 15-HETE and PGE2 were not statistically different between placebo and frusemide days. The procedure was well tolerated and instillation of placebo (saline) and frusemide only caused minor symptoms. Figure 1 shows the effect of frusemide v placebo on PGE2 production by human nasal mucosa in vivo. After nasal lavages, PGE2 basal concentration in nasal secretions showed a progressive decrease starting at 30 minutes (1 15 (16) pg/ml for placebo and 106 (19) pg/ml for frusemide), reaching the lowest values (54 (9) pg/ml and 55 (9 6) pg/ml) at 60 minutes. No significant changes in PGE2 production were found between placebo and frusemide instillation. Figure 2 shows the effect of frusemide on 15-HETE production. As for PGE2, no differences in the production of this arachidonic acid metabolite were found in basal values between the placebo day and the frusemide day. The production of 15-HETE decreased progressively starting at 15 minutes (777 (291) pg/ml for placebo and 592 (170) pg/ml for frusemide) and reached the lowest concentration at 60 minutes (328 (79) pg/ml and 330 (49) pg/ml respectively). There were no statistical differences between placebo and frusemide instillation.
PGE2
Discussion
The bronchoconstrictor response in asthma depends on a complex interaction between inflammatory cells and their products, epithelial cells, neural pathways, and airway smooth muscle. Frusemide may prevent asthmatic responses by interfering with one or more of the mechanisms involved in asthma.12418 For instance, Anderson and coworkers19 have reported that frusemide may prevent the release of histamine and leukotrienes from human lung tissue passively sensitised to Dermatophagoides pteronyssinus. The relevance of these in vitro findings to in vivo allergen induced asthma has yet to be evaluated.
Frusemide is an inhibitor of sodiumpotassium chloride cotransport located in the basolateral cell membrane.20 Mucosal application of frusemide, however, had no effect on cotransport function.4 20 Another diuretic, amiloride, shows a greater effect than frusemide on epithelial ion flux but it does not prevent bronchoconstriction. 4 Altogether, these findings suggest that inhibition of ion transport cannot account for the protective effect of frusemide. On the other hand, studies have shown that the antiasthmatic effect of frusemide is unlikely to be due to a direct effect on smooth muscle contraction.'8 The protective effect of frusemide on cough induced by low chloride (Cl-) solution indicates that it might protect from bronchospasm by acting on airway sensory nerves but confirmation of this hypothesis requires further studies. 4 Inhaled PGE2, like inhaled frusemide, may inhibit bronchoconstrictor response to allergen, exercise, and metabisulphite.7 These findings, together with the reported stimulatory effect of frusemide on PGE2 release,6 suggest that frusemide might prevent bronchospasm by enhancing PGE2 production in the respiratory mucosa. The results of the present study, however, do not support this hypothesis. 1 5-HETE and other metabolites formed from arachidonic acid via 1 
